The abstract is read at the publisher; the summary is JClub's.
Maintenance intravenous ketamine in treatment-resistant bipolar depression reduced MADRS scores from 19.8 to 15.6 over 12 weeks, with a mean difference of -4.20 (p = 0.009).
- Why it matters: Relapse after an induction course is common in depressive disorders, but maintenance ketamine safety and efficacy in treatment-resistant bipolar depression are not well established.
- What they did: In a single-arm, open-label 12-week extension, 36 participants received up to six flexibly dosed infusions (0.5–1.0 mg/kg), and MADRS change was analyzed with a linear mixed-effects model.
- The result: Response rose from 33.3% to 50% and remission from 27.8% to 36.1%, while suicidal ideation declined from 54.3% to 20.7% and no treatment-emergent mania or psychosis occurred.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.